Trial Profile
A phase I/IIa, open-label, three-stage, study to investigate the safety, the efficacy and the pharmacokinetics of Niclosamide enemas in subjects with active Ulcerative Proctitis or Ulcerative Procto-Sigmoiditis
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 16 Feb 2023
Price :
$35
*
At a glance
- Drugs Niclosamide (Primary)
- Indications Ulcerative proctitis; Ulcerative proctosigmoiditis
- Focus Adverse reactions; First in man
- Sponsors First Wave Bio
- 28 Nov 2022 Status changed from active, no longer recruiting to discontinued.
- 20 Oct 2022 Planned primary completion date changed from 1 Sep 2022 to 1 Oct 2022.
- 26 Aug 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Sep 2022.